Recent studies delineating molecular alterations in pancreatic cancer and germline alterations in individuals with pancreatic cancer highlight the need to understand the changing landscape of clinical tools available for diagnosing and treating this cancer effectively.

Systemic therapy is an area of active research for pancreatic cancer. Given the increase in pancreatic cancer mortality rates, it is important for clinicians to stay up-to-date with the most recent trial data and existing challenges in systemic therapy development for pancreatic cancer.

This activity will address the increasing use of PARP inhibitors in the management of patients with solid tumors, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.

Continued education regarding the management of pancreatic cancer is required to bridge the gap in cancer care and improve outcomes in the patient population.

Systemic therapy options in metastatic pancreatic cancer are evolving, including increasing usage of maintenance therapies. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.

Systemic therapy options in metastatic pancreatic cancer are evolving, including increasing usage of maintenance therapies. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.

The approval of therapies indicated for patients with rare mutations and the recommendation for testing all patients with pancreatic cancer has changed the testing and treatment landscape significantly. Health care professionals (HCP) need to be well versed in the potential for actionable mutations and how to counsel patients accordingly.